Thanks @Quiltman, that's interesting reading. I noticed that they seem to think it works in a sub group's of patients who hadn't previously taken Relyvrio. Another nail in the coffin for Amylyx' drug. I wonder what SLS-005's phase 1 results looked like and how many patients they had to gain ODD from the FDA?
It highlights how a phase 2/3 can uncover unknown issues when a greater number of patients with different histories are trialed. I wonder if any of our phase1 patients had ever been on Relyvrio?
PharmAust media thread, page-272
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.015(8.57%) |
Mkt cap ! $75.22M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.0¢ | 18.0¢ | $340.2K | 1.839M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 85126 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 159277 | 2 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
19.0¢ |
Change
0.015 ( 7.22 %) |
||||
| Open | High | Low | Volume | ||
| 18.0¢ | 19.0¢ | 18.0¢ | 1360996 | ||
| Last updated 15.51pm 14/05/2024 ? | |||||
| PAA (ASX) Chart |